Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 7/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19454675 | 0.88 | CNR2 (0.44) | CNR2CHRM4GPR119CYP3A4CYP2C19 | |
| SCHEMBL29504590 | 0.85 | GPR119 (0.49) | CNR2GPR119CYP3A4CYP2C19 | |
| SCHEMBL19434765 | 0.85 | GPR119 (0.49) | CNR2GPR119CYP3A4CYP2C19 | |
| SCHEMBL21643090 | 0.79 | GPR119 (0.46) | GPR119ACACB | |
| SCHEMBL29504628 | 0.77 | CNR2 (0.50) | CNR2CHRM4GPR119CYP3A4CYP2C19 | |
| SCHEMBL19434953 | 0.77 | CNR2 (0.50) | CNR2CHRM4GPR119CYP3A4CYP2C19 | |
| SCHEMBL20943620 | 0.75 | CNR2 (0.39) | CNR2CHRM4GPR119CYP3A4CYP2C19 | |
| SCHEMBL19454580 | 0.73 | CNR2 (0.51) | CNR2CHRM4GPR119CYP3A4CYP2C19 | |
| SCHEMBL19434851 | 0.73 | CNR2 (0.46) | CNR2CHRM4GPR119CYP3A4CYP2C19 | |
| SCHEMBL29504481 | 0.73 | CNR2 (0.46) | CNR2CHRM4GPR119CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919915-B2 | Compounds as GPR119 agonists | MANKIND PHARMA LTD. (IN) | 2021-02-16 | — | — | US | disclosed |
| US-20200040006-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200040006-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | GPR119, GPR84, GPR65 | CNR2 71/4885CHRM4 304/4885GPR119 1/4885 |
| US-10919915-B2 | Compounds as GPR119 agonists | GPR119, GPR84, GPR65 | CNR2 72/4885CHRM4 275/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.